Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Agenovir

Agenovir?uq=x1rNslWr
2014 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
Description

Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Primary Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Agenovir’s full profile, request a free trial.

Agenovir Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 09-May-2018 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 17-May-2016 000.00 000.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2016 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Agenovir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Agenovir Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
California Institute for Quantitative Biosciences Accelerator/Incubator 000 0000 000000 0
Celgene Corporation Minority 000 0000 000000 0
Data Collective Venture Capital Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Agenovir Executive Team (5)

Name Title Board
Seat
Contact
Info
Dirk Thye MD Chief Executive Officer, President and Board Member
Bolyn Hubby Ph.D Chief Scientific Officer
Stephen Quake Ph.D Co-Founder, Board Member & Chairman of the Scientific Advisory Board
Angela Wu Co-Founder & Advisor

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

Agenovir Board Members (4)

Name Representing Role Since Contact
Info
Bruce Hironaka JD Agenovir Board Member 000 0000
Stephen Quake Ph.D Agenovir Co-Founder, Board Member & Chairman of the Scientific Advisory Board 000 0000
William Smith Agenovir Board Member, Intellectual Property 000 0000

1 Former Board Member

You’re viewing 3 of 4 board members. Get the full list »